Dn B Asset Management As Regeneron Pharmaceuticals, Inc. Transaction History

Dn B Asset Management As

$19.9 Billion
Q2 2024

A detailed history of Dn B Asset Management As transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Dn B Asset Management As holds 32,430 shares of REGN stock, worth $36.7 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

32,430

Previous 31,234 3.83%

Holding current value

$36.7 Million

Previous $30.1 Million 13.38%

% of portfolio

0.17%

Previous 0.17%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 05, 2024	BUY	$883.2 - $1071.19 $1.06 Million - $1.28 Million	1,196 Added 3.83%	32,430 $34.1 Million
Q1 2024 Apr 12, 2024	SELL	$902.69 - $993.35 $955,948 - $1.05 Million	-1,059 Reduced 3.28%	31,234 $30.1 Million
Q4 2023 Jan 04, 2024	BUY	$775.18 - $881.7 $1.19 Million - $1.35 Million	1,532 Added 4.98%	32,293 $28.4 Million
Q3 2023 Oct 13, 2023	BUY	$692.45 - $844.37 $1.03 Million - $1.25 Million	1,482 Added 5.06%	30,761 $25.3 Million
Q2 2023 Jul 06, 2023	BUY	$700.03 - $830.35 $5.24 Million - $6.22 Million	7,492 Added 34.39%	29,279 $21 Million
Q1 2023 Apr 20, 2023	BUY	$680.49 - $826.97 $854,014 - $1.04 Million	1,255 Added 6.11%	21,787 $17.9 Million
Q4 2022 Jan 12, 2023	SELL	$705.89 - $766.39 $148,942 - $161,708	-211 Reduced 1.02%	20,532 $14.8 Billion
Q3 2022 Oct 11, 2022	SELL	$573.97 - $724.32 $5.82 Million - $7.34 Million	-10,140 Reduced 32.83%	20,743 $14.3 Million
Q2 2022 Jul 08, 2022	SELL	$548.35 - $738.84 $913,551 - $1.23 Million	-1,666 Reduced 5.12%	30,883 $18.3 Billion
Q1 2022 Apr 08, 2022	SELL	$595.12 - $698.43 $755,802 - $887,006	-1,270 Reduced 3.76%	32,549 $22.7 Million
Q4 2021 Jan 12, 2022	SELL	$543.48 - $670.97 $3.49 Million - $4.31 Million	-6,429 Reduced 15.97%	33,819 $21.4 Million
Q3 2021 Oct 15, 2021	SELL	$574.03 - $680.96 $4.04 Million - $4.8 Million	-7,043 Reduced 14.89%	40,248 $24.4 Million
Q2 2021 Jul 06, 2021	BUY	$472.8 - $558.54 $2.46 Million - $2.9 Million	5,195 Added 12.34%	47,291 $26.4 Billion
Q1 2021 Apr 15, 2021	BUY	$446.73 - $548.2 $2.23 Million - $2.74 Million	4,992 Added 13.45%	42,096 $19.9 Million
Q4 2020 Jan 19, 2021	BUY	$478.3 - $607.98 $380,248 - $483,344	795 Added 2.19%	37,104 $17.9 Million
Q3 2020 Oct 14, 2020	SELL	$544.75 - $658.21 $22.5 Million - $27.2 Million	-41,284 Reduced 53.21%	36,309 $20.3 Million
Q2 2020 Jul 08, 2020	BUY	$493.32 - $643.92 $5.55 Million - $7.24 Million	11,248 Added 16.95%	77,593 $48.4 Billion
Q1 2020 Apr 17, 2020	BUY	$336.18 - $494.43 $1.49 Million - $2.19 Million	4,436 Added 7.17%	66,345 $32.4 Million
Q4 2019 Jan 13, 2020	BUY	$274.13 - $376.51 $3.11 Million - $4.27 Million	11,339 Added 22.42%	61,909 $23.2 Million
Q3 2019 Oct 16, 2019	BUY	$273.46 - $318.39 $5.13 Million - $5.97 Million	18,751 Added 58.93%	50,570 $14 Million
Q2 2019 Jul 08, 2019	SELL	$299.6 - $414.82 $5.27 Million - $7.29 Million	-17,580 Reduced 35.59%	31,819 $0
Q1 2019 Apr 11, 2019	SELL	$372.08 - $439.57 $1.53 Million - $1.8 Million	-4,099 Reduced 7.66%	49,399 $0
Q4 2018 Jan 15, 2019	BUY	$335.82 - $403.04 $10.4 Million - $12.4 Million	30,868 Added 136.4%	53,498 $20 Million
Q3 2018 Oct 10, 2018	BUY	$351.14 - $408.51 $7.95 Million - $9.24 Million	22,630 New	22,630 $0
Q2 2018 Jul 06, 2018	SELL	$284.6 - $344.99 $7.51 Million - $9.11 Million	-26,400 Closed	0 $0
Q1 2018 Apr 11, 2018	BUY	$315.82 - $393.78 $663,222 - $826,938	2,100 Added 8.64%	26,400 $0
Q4 2017 Jan 10, 2018	BUY	$358.63 - $469.95 $8.71 Million - $11.4 Million	24,300	24,300 $0

Others Institutions Holding REGN

# of Institutions

1,460

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $121B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dn B Asset Management As, based on Form 13F filings with the SEC.

News

Stay updated on Dn B Asset Management As with notifications on news.

Account

Dn B Asset Management As Regeneron Pharmaceuticals, Inc. Transaction History